Clinical Implications of Triple Combination Therapies (Metformin + Alpha-glucosidase Inhibitor + DPP-4 Inhibitor) in Type 2 Diabetes

Trial Profile

Clinical Implications of Triple Combination Therapies (Metformin + Alpha-glucosidase Inhibitor + DPP-4 Inhibitor) in Type 2 Diabetes

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2014

At a glance

  • Drugs Anagliptin (Primary) ; Metformin; Miglitol
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Sponsors Sanwa Kagaku Kenkyusho
  • Most Recent Events

    • 18 Jun 2014 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
    • 13 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
    • 06 Mar 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top